Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
Oncotelic announced publication of a peer-reviewed Biomedicines study using its AI-driven PDAOAI platform to identify a four-gene prognostic signature (FKBP1A, EIF4E, RRAGC, PPARGC1A) in hepatocellular carcinoma. The signature was independently validated in a Japanese HCC cohort of 203 patients and defines patient stratification for planned clinical trials of Sapu003, an intravenous formulation of everolimus.
Key figures
- Drug Name
- Sapu003 (intravenous everolimus)
- Target vectors
- approximately 100 billion
- Gmp bio interest
- 45%
- Gene signature count
- 4
- Validation cohort patients
- 203
- Platform index pubmed abstracts
- approximately 29 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.